Vimizim’s Briefing Docs Signal Smooth FDA Panel for Biomarin
By Randy Osborne
Friday, November 15, 2013
Likely breathing easier ahead of Tuesday’s FDA advisory committee meeting is Biomarin Pharmaceutical Inc., with Vimizim (elosulfase alfa) slated to undergo scrutiny as an enzyme replacement therapy (ERT) for mucopolysaccharidosis Type IVA, also called Morquio A syndrome.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.